Skip to main content

For journalists

Press

Menopause has a map now. Web + iOS + Android live.

Victoria, B.C.Web · iOS · Android

Nila is an evidence-graded, community-powered menopause platform built by a survivor. Now live on web, iOS, and Android. Interview slots with founder Erin Beattie are limited. Contact info@hellonila.com.

In this kitLatest release ↓Download assets ↓
Latest releaseVictoria, B.C. · August 28, 2026

Nila launches full Apple Health and Health Connect integration — with a firm rule: your data gets shown, never scored

Victoria, BC — August 28, 2026 — Nila, an evidence-graded menopause support platform and member of Femtech Canada and The Menopause Society, today announced its Apple Health and Health Connect integration is fully live across iOS and Android — bringing sleep, steps, resting heart rate, heart rate variability (HRV), and cycle days into the app — alongside a product-wide commitment never to convert imported wearable data into a score, grade, or verdict.

The update comes as Apple rolls out native perimenopause tracking in iOS 27 and as more of the menopause-app category leans on wearables to power symptom insights. Alongside the launch, Nila is opening conversations with employers, benefits providers, and potential partners interested in bringing evidence-based menopause support to the people they serve.

Nila is built and run by a single founder, Erin Beattie, who shipped this launch eleven months after finishing active treatment for breast cancer — and while in the middle of her own surgical menopause.

Built through diagnosis, surgery, and menopause — not before it, or after it

Erin lived with undiagnosed endometriosis for nearly twenty years before she was diagnosed with hormone-positive breast cancer in September 2023. Treatment — including Tamoxifen and Zoladex — deliberately suppressed her estrogen, inducing chemical menopause. She had a bilateral mastectomy in February 2024 and reconstruction in February 2025. In September 2025, her gynecologist and oncologist recommended a total hysterectomy with bilateral salpingo-oophorectomy (BSO) — prompted by continued endometriosis suspicion and an MSH2 gene flag — and the surgery confirmed stage 3 endometriosis that had gone undetected for two decades. The BSO put her into full surgical menopause on top of the chemical menopause already underway. Because her cancer is hormone-positive, systemic HRT remains a genuinely open question for her care team; eleven months out from surgery, the menopause is acute and all-consuming some days. She manages it with local vaginal estrogen and the same Nila tools she built for everyone else: workouts, nutrition, and research.

She built Nila the entire time — through diagnosis, two major surgeries, reconstruction, and the acute menopause she is living through right now. Nila is not a product she built after her health crisis, informed by hindsight. It is one she built inside it, in real time, without outside funding or a team.

What one founder built, and why

This week, Nila’s full Apple Health and Health Connect integration went live — on both iOS and Android, pulling in sleep, steps, resting heart rate, heart rate variability, and cycle days. Nila has one non-negotiable: your data shows up exactly as your phone or watch reports it, never twisted into a score or a verdict. Balance, the market-leading menopause app used by over a million people, still does not have this on either platform — and Erin does not know of another menopause-specific platform pairing full cross-platform wearable integration with a hard no-score policy.

That gap is the product of a specific point of view: Erin built Nila because she spent nearly twenty years not being believed about what was happening in her own body, then had to become her own advocate through a cancer diagnosis and a surgical menopause in real time. Nila exists so that other people can walk into a doctor’s appointment already informed — with their own data, in plain language, backed by graded sources — instead of starting from zero the way she had to.

What’s live

Members on any account tier can now bring in five core Vitals from Apple Health (iOS) or Health Connect (Android):

  • Sleep
  • Steps
  • Resting heart rate
  • Heart rate variability (HRV)
  • Cycle days

This is the full integration Nila has been building toward — not an incremental add-on, but the complete set of Vitals launching together across both platforms at once.

Members choose exactly what to bring in, one metric at a time. Nila stores a single daily total per measure — never raw, minute-by-minute readings — and any of it can be deleted at any time. A dedicated explainer, Where your numbers go, walks through the full data path before anyone connects anything.

Bring in the wearable you already have

Members using Fitbit, Garmin, Oura, Withings, or Whoop can bring their data into Nila today — routed through Apple Health or Health Connect, the same path as every other metric. No separate account, no extra setup: if a wearable already writes to Apple Health or Health Connect, Nila can read it.

Why the “no score” line matters

Nila’s core promise is that its research library only carries evidence with a named source and a visible grade — A through D — so users can check the underlying study themselves. The same discipline now applies to the numbers a phone or watch estimates about a body: sleep hours, resting heart rate, HRV, and so on are shown exactly as the device reported them, with a standing note that these are estimates, and that how a night actually felt should outweigh what a device says about it. Nila does not convert this data into a score, a colour-coded verdict, or an interpretation of what it means — a design constraint that is now enforced in the product itself, not just stated as a policy.

That stands in contrast to the direction much of the category has moved: dedicated symptom scores, AI-generated readiness assessments, and wearable-driven “detection” features are increasingly common across menopause apps, and Apple’s own iOS 27 update adds automated perimenopause notifications based on logged cycle data. Nila’s explainer at Nila and Apple Health lays out plainly what the phone already does on its own and what Nila adds on top of it — namely a graded research library, a doctor-ready pattern view, a vetted practitioner directory, and an AI assistant that answers only from that library.

Why this matters for employers and benefits providers

Menopause-related productivity loss costs the U.S. economy more than $26 billion a year, according to a 2023 Mayo Clinic Proceedings study — split between lost work time and direct medical costs among women aged 45 to 60. Roughly 1 in 9 women in that study missed work in the past year due to symptoms, and most employer benefits plans still do not address menopause specifically.

Nila is built to be something employers and benefits providers can put in front of their people directly: a graded, sourced research library instead of forum threads; symptom tracking that produces a doctor-ready summary instead of a spreadsheet; and a practitioner directory to help employees find the right specialist faster. Nila is open to conversations with employers, insurers, and benefits platforms interested in piloting access for their teams or members.

Built for the moment before the specialist appointment

Nila is not designed to replace a doctor, a gynecologist, or an oncologist — it is designed for everything that happens before that appointment: understanding what is normal, what is worth tracking, and what questions to ask. The goal is for someone to walk into a specialist’s office already informed, with their own patterns and data in hand, rather than starting the conversation from zero.

What’s next

Further integrations — including a public Oura connection, and support for reading data directly from other wearables rather than via Apple Health or Health Connect — remain gated behind member demand. Nila has set a public threshold: once 250 people register interest in a specific integration, the company commits to publishing a cost and timeline, rather than leaving it open-ended.

About Nila

Nila is a free-to-start menopause support platform offering an evidence-graded research library (400+ articles, each carrying a sourced A–D grade), symptom tracking with doctor-ready exports, a vetted practitioner directory, and an AI assistant that answers only from Nila’s own graded sources. Nila is a member of Femtech Canada and The Menopause Society. Nila is available on the App Store and Google Play.

Nila is founded, built, and run by Erin Beattie of Victoria, BC — a breast cancer survivor eleven months out from active treatment, currently in surgical menopause following a total hysterectomy with BSO. Nila is entirely bootstrapped — self-funded, with no outside investors — and Erin remains the platform’s sole founder.

Media contact: Erin Beattie, Founder · info@hellonila.com · hellonila.com/press

Partnership, employer, and benefits inquiries: partnerships@hellonila.com

At a glance

The fast facts

A freemium, evidence-graded community, research library, and care toolkit for perimenopause and menopause. Founded by a Victoria-based communications professional and cancer survivor who was pushed into menopause chemically and then surgically, and found almost no map for any of it.

Platform launchedMay 21, 2026
iOS app launchedJune 30, 2026
Android app launchedAugust 3, 2026
Verified practitioner directory launchedJuly 20, 2026
FoundedVictoria, BC, Canada
Free tierCommunity, 82 symptom guides, relief finder (350+ options), daily check-in, five loved-one guides, free permanently
PremiumCAD $12.99/month or $129/year
Nila for Teamsfrom CAD $39 (health plan) to CAD $79 (direct) per seat/year, for teams of 10 to 250+ employees
Partner revenuePaid sponsorships, practitioner directory featured listings, and research collaborations, always clearly labelled, not inside the member paywall
FundingSelf-funded to date; in early conversations with investors
MembershipsFemtech Canada · The Menopause Society Hub · listed in the FemTech Observatory 2026
Workplace pledgeSignatory of the Wellbeing of Women Menopause Workplace Pledge
Editorial reviewClinical content reviewed by Jill Palko, MD, FACOG, board-certified OB/GYN. A dedicated SOGC-aligned Canadian evidence piece is in review and publishes soon.
Why nowThe evidence, access, and funding gapMarket size, funding disparity, and the $3.5B Canadian cost of unmanaged menopause, with sources.

British Columbia began offering free public coverage of hormone replacement therapy in March 2026. Western Canada's first Complex Menopause Clinic opened at BC Women's Hospital in 2025. The FDA removed its black-box warning for systemic estrogen in November 2025. In August 2026, GreenShield and Women's Health Collective Canada announced funding for Can-RISE, the first national investigator-led study of perimenopause, menopause and post-menopause in Canada. Globally, an estimated 1.2 billion women will be in or past menopause by 2030, roughly one in seven people on the planet. The average time from a woman's first perimenopause symptom to diagnosis is still 4.6 years (Newson Health). Nila is built to close that gap.

The investment picture hasn't caught up. Roughly 6% of private healthcare investment goes to women's health, even after a record US$2.6B year in 2024 (SVB, 2025). Between 2019 and 2023, companies working on erectile dysfunction raised US$1.24B while endometriosis, a condition affecting an estimated 190 million people with a 7-to-10-year diagnostic delay, drew just US$44M (npj Women's Health, 2024). Less than 1% of healthcare funding in that window went to women-specific conditions (McKinsey Health Institute, 2025). Women weren't required in US clinical trials until 1993.

The FemTech market is projected to grow from US$39B (2024) to US$97B (2030); the untapped menopause-medication market alone is estimated at US$120–230B annually. McKinsey and the WEF put the prize for closing the broader women's-health gap at US$1T in GDP and roughly 137 million more women in full-time work by 2040, about $3 returned for every $1 invested. A 2026 analysis from the World Economic Forum, Kearney Health Institute, the Gates Foundation, and Wellcome Leap specifically identified menopause as under-resourced relative to its disease burden.

In Canada, unmanaged menopause symptoms cost the Canadian economy an estimated $3.5 billion a year: $3.3 billion in lost income borne by women themselves (reduced hours, reduced pay, or leaving the workforce) and $237 million in lost employer productivity, roughly 540,000 lost workdays.

Sources: SVB Innovation in Women's Health (2025); npj Women's Health (2024); McKinsey Health Institute (2025); Grand View Research FemTech market; WEF/Kearney/Gates/Wellcome Leap (2026); Menopause Foundation of Canada, Menopause and Work in Canada (Deloitte / Leger, October 2023); GreenShield and WHCC fund first national study on menopause in Canada (Benefits and Pensions Monitor, August 2026).

What makes it differentThe editorial lineFive things that separate Nila from a symptom tracker: platform scope, loved-one guides, named pathways, evidence grading, doctor-ready outputs.
  • A full platform. The chat, community, research library, symptom guides, and a private daily check-in are equally central parts of the product.
  • Guides for loved ones. Five free guides for a partner, her kids (teens or grown), her closest friend, the adult child of a postmenopausal mother, and a couples-conversation guide with six scripted openings. No competitor product addresses the support network directly.
  • Built for whom the research left out. Twenty named pathways include neurodivergent women (the ADHD/autism–perimenopause connection), post-cancer menopause, Black women (whose vasomotor symptoms last a median of 10.1 years vs. 7.4 overall), trans and non-binary hormone journeys, and sole carers, plus a standalone research-gaps page naming where the evidence is thinnest, with sources. The full breakdown lives at hellonila.com/who-this-is-for: one door, no single-axis choice required.
  • Evidence-graded and dated. Every research card carries an Evidence A/B/C strength tag and a region tag (Global, Canada, US, UK, or Personal for lived-experience essays). The library is updated roughly every quarter; affiliate links and paid placement aren't part of it.
  • Doctor-ready by design. A clinician-questions worksheet compiles selections from across the site into a printable appointment summary; Premium adds a one-page health record pulling together check-in trends, supplements, and profile.

Lane-by-lane comparison: hellonila.com/why-nila

Two months in

By the numbers

Nila launched May 21, 2026. Since then the community has grown to 155 members, with more than a third joining in the past 30 days. Members have opened 106 chat sessions with the Nila chatbot, exchanging over 590 messages, alongside symptom logs, weekly check-ins, and saved items in personal stacks. The newsletter, published bi-weekly on LinkedIn, has reached 815 subscribers, with weekly site traffic more than tripling since launch.

Behind it: 409 research articles, built and edited by a single founder in under three months; eleven verified practitioners now listed in the directory; and a partnership inquiry underway. The iOS app carries a 5-star rating from its early reviewers; the Android app is in closed testing. For a solo-built health platform in its first 60 days, these numbers reflect both meaningful engagement and genuine unmet need.

Community partners

The people we’re walking alongside

Small, chosen relationships — not sponsors, not advertisers. Each partner has a public room on Nila explaining what we’re doing together. See the latest on the News page.

Download

Press kit

In the news

Coverage

Selected coverage and mentions now live on the News page. More on the way — reach out via info@hellonila.com for interviews or review access.

Founder

Erin Beattie

Erin Beattie is the editor, researcher, developer, founder, and funder behind Nila. Her path to building it began eighteen years earlier, with undiagnosed endometriosis. In September 2023, she was diagnosed with hormone-positive breast cancer. Treatment, including Tamoxifen and Zoladex, deliberately suppressed her estrogen, inducing chemical menopause. A hysterectomy prompted by MSH2 gene flags (a marker for Lynch syndrome) followed; that surgery is where her endometriosis was finally confirmed, and it triggered full acute surgical menopause. Because her cancer is hormone-positive, systemic HRT remains a genuinely open question for her; she currently uses local vaginal estrogen, with research on further options still evolving. That gray zone, neither cleared for hormone therapy nor ruled out from it, is central to why Nila is built for more than one kind of menopause story.

"Most of what's out there treats menopause as one story. Nila is built for the version that arrived after surgery, after cancer, alongside ADHD, or outside the timeline anyone prepared you for."
Erin Beattie, Founder

Photo · Bio · hellonila.com/about

For investors and partners

The investment and partnership case

Virtual menopause clinics (US$99–$379/month, regional, prescription-bound) have validated demand, but they leave the bigger half of the market unserved: moderated community, evidence-based research library, symptom and treatment guides, and a private companion at CAD $12.99/month, globally, for the populations clinics structurally don't serve — induced menopause, post-cancer, neurodivergent, trans and non-binary, women of colour, and sole carers.

Nila is self-funded to date and in early conversations with investors. Partnership inquiries span employer pilots, health plan bundles, research collaborations, and sponsored rooms that are always clearly labelled and not inside the member paywall.

Contact

For media inquiries — interview requests, review access, fact-checks, and higher-resolution assets — as well as funder conversations, employer pilots, and clinical or research partnerships. Founder available for intro calls.

info@hellonila.com · hellonila.com/partner

Memberships & affiliations

Not here for the press kit?

Start with what’s loudest today.

Two minutes, no account needed, and you’ll leave with a route instead of a reading list.